OMass Therapeutics is a biotechnology company developing novel small molecules for immunological and orphan diseases using proprietary biochemistry.

OMass is identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes. We are advancing a pipeline of small molecule …

We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on …

2023年4月19日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and …

OMass’ platform retains biological relevance at high resolution, delivering cell-system fidelity with cell-free precision. Faithful to the native ecosystem. We use proprietary biochemistry to …

2024年8月5日 · OMass has already made significant progress with its portfolio of highly-validated, yet intractable or inadequately drugged targets. OMass’ lead programme is an insurmountable …

OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress

At OMass, we take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our …

2025年2月26日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead programme is a best-in-class MC2 (melanocortin-2) …

2024年11月15日 · OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead programme is a best-in-class MC2 (melanocortin-2) …